What the FDA labels say about taking them together
Atorvastatin and sodium zirconium cyclosilicate
Sodium zirconium cyclosilicate's FDA label of February 8, 2024 names atorvastatin in its drug interactions section; the atorvastatin labels PlainMeds reads (2) do not name sodium zirconium cyclosilicate. The sodium zirconium cyclosilicate label: “However, there was an increase in systemic exposure to weak acids such as furosemide and atorvastatin, and a decrease in systemic exposure to weak bases such as dabigatran when co-administered with LOKELMA, as shown in …”
Check it at the source: the atorvastatin FDA label on DailyMed (effective April 15, 2024, Viatris Specialty LLC); the sodium zirconium cyclosilicate FDA label on DailyMed (effective February 8, 2024, AstraZeneca Pharmaceuticals LP).
What does the atorvastatin label say about sodium zirconium cyclosilicate?
Atorvastatin's label (effective April 15, 2024) and its 1 other brand-application label do not name sodium zirconium cyclosilicate in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Lipitor), NDA020702 (Upjohn), as published by Viatris Specialty LLC, effective April 15, 2024 (SPL set a60cc18b-0631-4cf0-b021-9f52224ece65), via openFDA; the full label on DailyMed
What does the sodium zirconium cyclosilicate label say about atorvastatin?
Sodium zirconium cyclosilicate label, drug interactionsHowever, there was an increase in systemic exposure to weak acids such as furosemide and atorvastatin, and a decrease in systemic exposure to weak bases such as dabigatran when co-administered with LOKELMA, as shown in Figure 2.
Source: FDA drug label (LOKELMA), AstraZeneca Pharmaceuticals LP, effective February 8, 2024 (SPL set 90bf8e28-748d-4e4b-a19f-9cf483370eff), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atorvastatin | Sodium zirconium cyclosilicate | |
|---|---|---|
| Labeled for | High cholesterol, Angina, High triglycerides, Heart attack and coronary artery disease | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.0228 per tablet 10 mg tablet | $28.33 per packet 10 gram powder packet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once